309 results on '"Jazaeri, Amir A."'
Search Results
2. A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
3. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer
4. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis
5. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
6. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab
7. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs
8. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer
9. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer
10. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction
11. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
12. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
13. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
14. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
15. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
16. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
17. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls
18. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
19. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation
20. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
21. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice
22. Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
23. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature
24. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer
25. Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from a Population-Based Study
26. Potential immunotherapy targets in recurrent cervical cancer
27. Immunotherapy in Gynecologic Cancers: Are We There Yet?
28. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
29. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia
30. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
31. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
32. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
33. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
34. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin
35. Erythema nodosum‐like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients
36. Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer.
37. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report.
38. Frailty: An outcome predictor for elderly gynecologic oncology patients
39. A nomogram for estimating the probability of ovarian cancer
40. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
41. Evaluation of EVI1 and EVI1s (Δ324) as potential therapeutic targets in ovarian cancer
42. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer
43. Transforming ovarian cancer care by targeting minimal residual disease
44. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease
45. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials.
46. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer.
47. A phase I study of tremelimumab, durvalumab, and hypofractionated radiotherapy for metastatic gynecologic cancers (040)
48. Exploring the utility of liquid biopsy (ctDNA) as a translational endpoint in clinical trials for endometrial cancer (012)
49. Diagramming the development of MDS/AML after treatment with PARP inhibitors (2290)
50. Obesity is associated with improved progression-free survival in MSI-H endometrial cancer treated with pembrolizumab (2260)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.